The goals of this paper are the following:

• to biologically classify multiple myeloma “based on known genetic subtypes with associated clinico-pathological associations”
• “to establish the prognostic value of known and new genetic factors for MM outcome, including the information generated through genomic tools”
• “to provide a framework for evaluation of new markers capable of serving as predictive for efficacy of novel therapeutics”

A general breakdown of myeloma cell categorization is as follows:

• Hyperdiploid cells (more inactive clinical features)
  • Trisomies
  • Deletion of chromosomes 13 and 17
  • Abnormalities of chromosome 1
    • 1p deletion and q1 amplification
• Non-hyperdiploid cells (more intensive clinical features)
  • IgH translocations
    • t(11;14)
    • (q13;q32)
    • t(4;14)
    • (p16;q32)
    • (q32;q23)

Authors:

R Fonseca, PL Bergsagel, J Drach, J. Shaughnessy, N Gutierrez, AK Stewart, G Morgan, B Van Ness, M Chesi, S Minvielle, A Neri, B Barlogie, WM Kuehl, P Liebisch, F Davies, S Chen-Kiang, BGM Durie, R Carrasco, Orhan Sezer, Tony Reiman, Linda Pilarski and H Avet-Loiseau

Click here to view article: